ストックスクリーナーアプリを入手
12.99
17.56%
1.94
前日終値:
$11.05
開ける：
$11.38
24時間の取引高:
734.20K
Relative Volume:
4.63
時価総額：
$187.35M
収益：
$6.39M
当期純損益:
$-117.26M
株価収益率:
-1.0408
EPS:
-12.4807
ネットキャッシュフロー:
$-79.08M
1週間 パフォーマンス:
+23.36%
1か月 パフォーマンス:
+30.29%
6か月 パフォーマンス:
+66.11%
1年 パフォーマンス:
+4.25%
1日の値動き範囲:
$11.23
$13.29
1週間の範囲:
$10.50
$13.29
52週間の値動き範囲:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
12.99 | 187.35M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-11-13 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Raymond James | Strong Buy |
| 2024-08-14 | 開始されました | William Blair | Outperform |
| 2024-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-02-27 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-29 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-10 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-01-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 開始されました | Cowen | Outperform |
| 2019-10-28 | 開始されました | Goldman | Buy |
| 2019-10-28 | 開始されました | JP Morgan | Overweight |
すべてを表示
Korro Bio Inc (KRRO) 最新ニュース
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? - Yahoo Finance UK
Korro Bio COO Chappell sells $34,309 in company stock By Investing.com - Investing.com South Africa
Korro Bio COO Chappell sells $34,309 in company stock - Investing.com UK
Korro Bio Inc (KRRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Korro Bio Inc (KRRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Korro Bio Inc (KRRO) Institutional Confidence - TradingKey
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Korro Bio Inc (KRRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Korro Bio Inc (KRRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Korro Bio Inc (KRRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Korro Bio: RNA Editor Plots Way Back After AATD Study FailI'm Holding (NASDAQ:KRRO) - Seeking Alpha
KRRO Q1 2026 Earnings: Narrowed Loss Surprises to the Upside, Shares RallyEarnings Surprise Stocks - newsline.com
KORRO BIO INC (KRRO) Stock Chart - ChartMill
Korro Bio Stockholders Approve Directors, Pay and Auditor - The Globe and Mail
Korro Bio (KRRO) director Ali Behbahani receives 14,677 stock options grant - Stock Titan
Korro Bio (KRRO) director receives 14,677 stock options at $10.59 strike - Stock Titan
Korro Bio (KRRO) director Nessan Bermingham receives 14,677 stock options at $10.59 - Stock Titan
Korro Bio (KRRO) director awarded 14,677 stock options at $10.59 strike price - Stock Titan
Director at Korro Bio (NASDAQ: KRRO) awarded stock options for 14,677 shares - Stock Titan
Korro Bio (NASDAQ: KRRO) director receives 14,677 stock options grant - Stock Titan
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
One Korro Bio Insider Raised Stake By 19% In Previous Year - Yahoo Finance
KRRO Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absencePerformance Review - newsline.com
KRRO Q1 2026 Earnings: EPS Beat But Stock Declines Amid No RevenueAnnual Report - newsline.com
KRRO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue PhaseManagement Tone Analysis - newsline.com
Korro Bio CEO Ram Aiyar sells $196,672 in company stock By Investing.com - Investing.com Nigeria
Korro Bio CEO Ram Aiyar sells $196,672 in company stock - Investing.com
Korro Bio (KRRO) CEO sale covers tax on performance stock unit - Stock Titan
Korro Bio director sells $39,897 in common stock By Investing.com - Investing.com Canada
Korro Bio director sells $39,897 in common stock - Investing.com
Korro Bio Inc. (KRRO) Faces Selling Pressure as Shares Retreat 3.21%Bear Pennant - The Legal Advocate
KRRO Q1 2026 Earnings: EPS Beat by 10.05% as Biotech Advances PipelineNext Quarter Guidance - The Legal Advocate
Press Release: Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors - Moomoo
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
Korro Bio | 4: Statement of changes in beneficial ownership of securities-Officer Aiyar Ram - Moomoo
Korro Bio, Inc. identifies surge in healthcare burden from ammonia in hepatic encephalopathy - Traders Union
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright - The Globe and Mail
Korro to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli
KRRO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionPreliminary Results - newsline.com
Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN
Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 – Minichart - Minichart
What is Korro Bio, Inc. (KRRO) stock_business overview_development history - Bitget
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa
Korro Bio Inc (KRRO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):